Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?
about
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockAntimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).2016 WSES guidelines on acute calculous cholecystitisCommunity-acquired pneumonia: identification and evaluation of nonrespondersDiagnostic value of soluble triggering receptor expressed on myeloid cells in paediatric sepsis: a systematic reviewUse of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series.Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsThe management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.2013 WSES guidelines for management of intra-abdominal infections.Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromesDevelopment and validation of a high-performance liquid chromatography method for determination of cefquinome concentrations in sheep plasma and its application to pharmacokinetic studies.WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachBloodstream infections in patients with liver cirrhosis.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Impact of serum biomarkers and clinical factors on intensive care unit mortality and 6-month outcome in relatively healthy patients with severe pneumonia and acute respiratory distress syndrome.Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.Management of antibiotic resistance in the intensive care unit setting.Current concept of abdominal sepsis: WSES position paper.Overview of antimicrobial therapy in intensive care units.Antimicrobial stewardship in the intensive care unit: a focus on potential pitfalls.Year in review 2010: Critical Care--Infection.Current trends in the management of cardiac implantable electronic device (CIED) infections.Using quality improvement principles to improve the care of patients with severe sepsis and septic shock.Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients.Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.Shortening the course of antibiotic treatment in the intensive care unit.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Septic shock due to NSTI caused by Actinomyces Turicensis: the role of clinical pharmacology. Case report and review of the literature.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.Antibiotic therapy in hematological neutropenic patients: what is the news?Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapyDaptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia.De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli.
P2860
Q24198268-1FDBBC4B-6368-4EBB-A77B-72C98CB38552Q24235566-97759A40-4B7D-433A-8812-FB2F16D8E8BAQ26739860-F8183E63-F800-4891-B7F7-93AC43730AEEQ26745734-8C814FAE-611B-446D-882E-9C47B1C3A8C4Q27002420-20A8E174-D8DF-4B8A-A40D-5B8F540AF19FQ28076186-E3F9DEC2-4C31-41B2-A36F-5E00337DD13BQ30396672-38A960E7-D1A0-4A5B-8A25-2B5AABCFC9A4Q30444028-FDD7F28C-B275-49FC-80E9-2BB7FB5C5485Q33552161-9BED4D40-5637-4F8A-878A-7DC96C7CA1A9Q33892834-B6A3644F-81F0-4A61-B3FF-09C002A730E4Q34290110-B16E0C6E-6829-4ADB-BF5D-1D1B23398C14Q34321150-A613C8E5-8C77-47BA-B5D1-44B9777821F1Q34425990-98818D02-05D2-467F-BD74-11E3CFB531F7Q34529375-FF96E3F1-9906-4E48-8458-B5878120EAC8Q34541183-5663FDB0-3A5B-4421-AA8D-7C1581D35122Q36396195-62BF37EB-599A-473F-9480-B0A2EAA6693EQ36913304-6BE7EEDD-3587-442F-B3A2-ECD1F0F45BEDQ37563029-7C494736-5E34-48AF-958A-7A0ED775D889Q37645053-0B494146-6A67-40DC-9A3E-E9D2E24F6042Q37692028-6EBEB23D-DFCC-4689-833B-913A0D624912Q37700552-3AB4BBCF-4043-4F0A-B582-B204DED7A0EBQ37702912-4586DB3D-FC48-44EC-9C2F-B2CF6C5541C9Q37822457-2F28B855-B2F9-4773-9152-BB4BE851606BQ37867266-5964AE66-DC0E-4F56-A36F-6445FBF5CA40Q37966018-7A95CDC2-3D31-48B6-A646-AF9E83CF7BE5Q38022551-F9812D69-408C-41DD-81E1-4FE5420F4E9BQ38139926-3ACCA057-E8DB-4B9A-AE1F-BA599C4A78B1Q38164668-DBE735AD-FC98-4EE2-A930-89E4B5131E57Q38232197-85682BA2-DF7C-4C62-B691-E6B17F277DD3Q38326541-EFA64F7A-59C2-49E2-A519-BDE854AF9FBEQ38341882-45706852-17DC-432F-AAF3-AFF05D41592FQ38790740-9D94AEB1-6EF2-4A88-92A4-8B7A525001EFQ39234057-C1605969-8262-4E4C-A744-4265FA66968EQ39344408-0FCCAEC9-E842-40E0-8EC4-E7F6BCE4E691Q39390126-96804A66-FA55-44E9-BE0E-9E4E97F2A01FQ40727311-644D9B5A-2201-48CE-B41B-A1EC5CC73F2CQ40817221-FA858F62-035C-46E8-849F-2D3D3F90FD24Q41435865-C6F5B16A-956F-4D80-8A22-6F56D7D0EFB5Q44373265-7D29C328-82E0-49C8-8BF2-51EBC5A3468FQ44449024-4B889C20-A7B4-4D63-AA09-EEBCB9E0F5B5
P2860
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@en
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@nl
type
label
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@en
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@nl
prefLabel
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@en
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@nl
P2860
P921
P356
P1433
P1476
Bench-to-bedside review: Appro ...... c shock--does the dose matter?
@en
P2093
Federico Pea
Pierluigi Viale
P2860
P2888
P356
10.1186/CC7774
P577
2009-06-10T00:00:00Z
P5875
P6179
1023002699